{"symbol":"GILD","fiscalQuarter":"Q3-2024","reportDate":"2024-11-06","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q3-2024","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Reaction Not Available","keyNumbers":[{"metric":"EPS","actual":"$2.02","expected":"N/A","surprise":"+28.01%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They emphasized ongoing commitment to innovation and pipeline development."],"summary":"Overall, management expressed confidence in the company's strategic direction. They noted positive trends in product demand despite market challenges."},"guidanceChanges":{"summary":"No guidance data was provided during the earnings call.","changes":[]},"whatItMeans":"Gilead Sciences reported a solid earnings surprise on EPS, indicating better-than-expected profitability. However, the lack of revenue data and stock reaction details leaves some uncertainty about market sentiment. Investors will be looking for more clarity on revenue performance and future guidance in upcoming reports.","metaDescription":"Gilead Sciences (GILD) Q3 2024 earnings: EPS beat by 28.01%. Stock reaction not available. Full breakdown."}}